Kitov Pharma Ltd.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. -2.80%35.610.9%$906.50m
JNJJohnson & Johnson -2.97%144.750.7%$901.63m
MRKMerck & Co., Inc. -3.69%82.640.7%$682.80m
ABBVAbbVie, Inc. -2.63%87.741.9%$645.81m
BMYBristol-Myers Squibb Co. -3.05%57.461.0%$552.74m
LLYEli Lilly & Co. -2.26%150.691.1%$539.56m
AZNAstraZeneca Plc -2.20%55.211.2%$247.49m
NVSNovartis AG -2.20%88.940.2%$162.84m
PRNBPrincipia Biopharma, Inc. -0.31%99.960.0%$117.69m
GSKGlaxoSmithKline Plc -3.03%38.070.2%$97.47m
CVACCureVac NV -4.55%49.720.0%$69.46m
NVONovo Nordisk A/S -1.51%68.390.1%$53.42m
RGENRepligen Corp. -4.34%139.667.1%$52.08m
OPKOPKO Health, Inc. 1.58%3.2211.2%$47.98m
SNYSanofi -3.72%50.490.2%$47.22m

Company Profile

Kitov Pharma Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack in June 2010 and is headquartered in Tel Aviv, Israel.